Osteoarthritis, Knee
Conditions
Brief summary
Osteoarthritis (OA) causes degradation and deformities of joints, including knees, hips, hands, and feet. Approximately more than 55% of populations above 45 years and more than 70% of population above 70 years will develop OA in at least one joint. The symptoms are dominated by pain but also stiffness and swelling occur. There is currently no cure for OA, and the ultimate treatment is joint replacement surgery. However, there is an unmet need to identify other treatment options that may delay or avoid surgery. Aquamid Reconstruction (AR) is a polyacrylamide hydrogel (PAAG) which is a non-degradable, highly visco-elastic synthetic gel, which is atoxic with durable effect and tissue-compatibility and well tolerated by mammal tissue by allowing in vivo vessel and fibrous in-growth. Experimental studies supported by histopathological observations have shown that AR exerts its effect via integration over time within the soft tissues, through a combination of vessel in-growth and molecular water exchange. Intra-articular injection of AR is expected to provide permanent pain relief and improve the functional ability through a cushioning or padding effect on the joint and thereby reduce symptoms and improve patients' quality of life. The purpose of this study is to obtain information of the safety and effectiveness of AR in patients with OA of the knee.
Interventions
DEVICEAquamid Reconstruction
AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile. The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle.
Sponsors
A2 Reumatologi Og Idrætsmedicin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * WOMAC pain score \>/= 5 * Kellgren and Lawrence radiographic scoring \>/= 1 * Signed informed consent form
Exclusion criteria
* Other diseases affecting the joints such as rheumatoid arthritis * Actual or recurrent infections requiring intravenous antibiotic treatment within the last 30 days or oral antibiotic treatment within the last 14 days before inclusion * Less than 12 weeks since injection of HA or corticosteroids in study-knee joint before treatment * Pregnancy or lactation * Not able to comply with the requirements of the study * Previous alloplasty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in the pain subscore of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) | 6 months | The WOMAC is a patient reported questionnaire that is easy to use and evaluates three domains; pain (five questions), stiffness (two questions) and physical function (17 questions), each weighted on a similar computation. The WOMAC Index is sensitive to change and is valid for elderly subjects with knee OA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in all subscores of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) | 3, 6 and 12 months | The WOMAC is a patient reported questionnaire that is easy to use and evaluates three domains; pain (five questions), stiffness (two questions) and physical function (17 questions), each weighted on a similar computation. The WOMAC Index is sensitive to change and is valid for elderly subjects with knee OA. |
| Participants' percieved effect | 1, 3, 6, and 12 months | Participants will be surveyed about the current state of the treated knee. Predefined answers are: Worsened; No change; Improved; Cured. |
Countries
Denmark
Contacts
Primary ContactAndreas Hartkopp, MD, PhD
Outcome results
None listed